ArticleKidney international2026
A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease.
Article in Kidney international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThis study investigated radiomic features extracted from magnetic resonance fingerprinting (MRF)-acquired T1 and T2 quantitative maps in children and young adults with autosomal dominant polycystic kidney disease (ADPKD) with normal kidney function and compared these features to those extracted from MRF images of healthy volunteers.
methodsMean T1 and T2 relaxation times, along with additional radiomic features, were derived from MRF T1 and T2 maps in 11 healthy volunteers and 18 patients with ADPKD. Two radiomic feature schemes were investigated to differentiate between patients with ADPKD and a healthy cohort using features from either the non-cystic kidney parenchyma or the entire kidney: mean T1 and mean T2 relaxation times alone and feature selection to identify radiomic features from the MRF T1 and T2 maps. Clinical models based on age, height-corrected total kidney volume (htTKV), and body surface area corrected TKV (BSA-TKV) were also investigated. The area under the receiver operating characteristic curve (AUC) was used to evaluate classification performance.
resultsMRF-derived mean T1 and T2 relaxation times in the non-cystic kidney parenchyma and the entire kidney were significantly greater for patients with ADPKD than for healthy volunteers. Combining radiomic features allowed for promising differentiation of patients with ADPKD and healthy volunteers using the non-cystic kidney parenchyma (AUC values: 0.79-0.99) and the entire kidney (AUC values: 0.92-0.96). The clinical biomarkers BSA-TKV and htTKV achieved AUC values of 0.86 and 0.72, respectively.
conclusionsThere was a strong ability to discriminate between patients with ADPKD and healthy volunteers using features from the non-cystic kidney parenchyma generated by MRF-based mean T2 and a combination of radiomic features extracted from either the MRF T1 or T2 map. Our study suggests that early alterations in non-cystic kidney parenchyma can detect the presence of ADPKD using radiomic features from MRF T1 and T2 maps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.